The Showa University Journal of Medical Sciences
Online ISSN : 2185-0968
Print ISSN : 0915-6380
ISSN-L : 0915-6380
Reduction of Ischemia-reperfusion Injury to Skin Flap by Treatment with Monoclonal Antibody to Endothelial Leukocyte Adhesion Molecule-1
Masakazu OHASHIYasuyoshi TOSAYoshiaki HOSAKAKaneshige SATOHMehmet OGUZ YENIDUNYABaohua PANG
Author information
JOURNALS FREE ACCESS

2007 Volume 19 Issue 3 Pages 137-145

Details
Abstract

The selectin family, which mediates adhesion of activated leukocytes to the vascular endothelium, plays an important role in inflammation. Endothelial leukocyte adhesion molecule-1 (SLAM-1) is expressed on activated vascular endothelium and mediates the special leukocyte rolling phenomenon seen when leukocytes adhere to vascular endothelium. We investigated changes in skin flap survival / necrosis due to treatment with the monoclonal antibody (Mab) to ELAM-1. Twenty-five male Sprague-Dawley rats (225-250 g) were used in the experiment. A 45 × 30 mm pedicled skin flap with superficial epigastric vessels was designed in the right inguinal region and prepared. Animals in the treated group received anti-ELAM-1 Mab intravenously 15 minutes prior to reperfusion ; those in the control group received normal saline. By tracing the outline of viable and nonviable areas skin flap viability was assessed. Data were collected for the subsequent 7 days. These data corroborated with histological evidence on comparable areas of the flap. Tracing analysis revealed an average flap survival area of 91.7% in the treated group and 18.3% in the control group (P < 0.005) . Histopathologically, few inflammatory changes were observed in the treated group, while marked damage was observed in the control group. We conclude that treating skin flaps with anti-ELAM-1 was effective in reducing ischemia-reperfusion (I-R) injury after 9 hours of warm ischemia.

Information related to the author
© The Showa Medical Association
Previous article Next article
feedback
Top